Review

easyseptm human cd138 positive selection kit ii (STEMCELL Technologies Inc)

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

STEMCELL Technologies Inc easyseptm human cd138 positive selection kit ii
$Inter-patient heterogeneity (A) UMAPs representing scRNA-seq data from enriched PCs from all patients with color codes representing unique samples (left), mPC and pPC populations (middle), and mPCs and pPCs by diagnosis (right). (B) Number of genes detected as dysregulated with a log2 FC of ≥ 0.5 or ≤ −0.5 when the analysis was conducted using all <t>CD138</t> + PCs, or CD138 + mPCs from each sample identified by scBCR-seq, using “ FindAllMarkers ” in Seurat. Horizontal lines indicate little to no difference in the number of DEGs, while upward lines indicate more DEGs found when the analysis focused only on the mPCs. ∗ indicates p ≤ 0.05; ∗∗ p ≤ 0.01; ∗∗∗ p ≤ 0.001; ∗∗∗∗ p ≤ 0.0001; and n.s. non-significant differences, as determined by the Wilcoxon test. (C) UMAP based on the single-cell transcriptome of a downsampled Seurat object with a color code of CytoTRACE score (left), and a superplot of the mean CytoTRACE score per sample group by diagnosis (right). Statistical testing was performed as in (B). (D) Boxplot of normalized UMIs detected in each sample, color coded by diagnosis, including myeloma-related markers, and commonly up- and down-regulated markers. (E) Heatmap of the fraction of PCs with myeloma IGH translocations detected by FISH (top), and boxplots of normalized UMIs of associated oncogene expression levels (next three rows). (F) Circos plots of three t(11;14) + myelomas evaluated by Lumpy using WGS data from germline and tumor-matched samples. (G) Heatmap of the fraction of cells with inferred large chromosomal gains (red) or losses (blue) in each PC population organized by diagnosis. Total number of PCs isolated and the fraction of mPCs in each sample are represented at the top. These plots include a dataset of pPC samples ( n = 4), and mPCs from patients with MGUS ( n = 11), SMM ( n = 22), NDMM ( n = 17), RRMM ( n = 15), and PCL ( n = 2).$
Easyseptm Human Cd138 Positive Selection Kit Ii, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/easyseptm human cd138 positive selection kit ii/product/STEMCELL Technologies Inc
Average 90 stars, based on 1 article reviews

easyseptm human cd138 positive selection kit ii - by Bioz Stars, 2026-06

90/100 stars

Images

1) Product Images from "Single-cell analysis of neoplastic plasma cells identifies myeloma pathobiology mediators and potential targets"

Article Title: Single-cell analysis of neoplastic plasma cells identifies myeloma pathobiology mediators and potential targets

Journal: Cell Reports Medicine

doi: 10.1016/j.xcrm.2024.101925

$Inter-patient heterogeneity (A) UMAPs representing scRNA-seq data from enriched PCs from all patients with color codes representing unique samples (left), mPC and pPC populations (middle), and mPCs and pPCs by diagnosis (right). (B) Number of genes detected as dysregulated with a log2 FC of ≥ 0.5 or ≤ −0.5 when the analysis was conducted using all CD138 + PCs, or CD138 + mPCs from each sample identified by scBCR-seq, using “ FindAllMarkers ” in Seurat. Horizontal lines indicate little to no difference in the number of DEGs, while upward lines indicate more DEGs found when the analysis focused only on the mPCs. ∗ indicates p ≤ 0.05; ∗∗ p ≤ 0.01; ∗∗∗ p ≤ 0.001; ∗∗∗∗ p ≤ 0.0001; and n.s. non-significant differences, as determined by the Wilcoxon test. (C) UMAP based on the single-cell transcriptome of a downsampled Seurat object with a color code of CytoTRACE score (left), and a superplot of the mean CytoTRACE score per sample group by diagnosis (right). Statistical testing was performed as in (B). (D) Boxplot of normalized UMIs detected in each sample, color coded by diagnosis, including myeloma-related markers, and commonly up- and down-regulated markers. (E) Heatmap of the fraction of PCs with myeloma IGH translocations detected by FISH (top), and boxplots of normalized UMIs of associated oncogene expression levels (next three rows). (F) Circos plots of three t(11;14) + myelomas evaluated by Lumpy using WGS data from germline and tumor-matched samples. (G) Heatmap of the fraction of cells with inferred large chromosomal gains (red) or losses (blue) in each PC population organized by diagnosis. Total number of PCs isolated and the fraction of mPCs in each sample are represented at the top. These plots include a dataset of pPC samples ( n = 4), and mPCs from patients with MGUS ( n = 11), SMM ( n = 22), NDMM ( n = 17), RRMM ( n = 15), and PCL ( n = 2).$
Figure Legend Snippet: Inter-patient heterogeneity (A) UMAPs representing scRNA-seq data from enriched PCs from all patients with color codes representing unique samples (left), mPC and pPC populations (middle), and mPCs and pPCs by diagnosis (right). (B) Number of genes detected as dysregulated with a log2 FC of ≥ 0.5 or ≤ −0.5 when the analysis was conducted using all CD138 + PCs, or CD138 + mPCs from each sample identified by scBCR-seq, using “ FindAllMarkers ” in Seurat. Horizontal lines indicate little to no difference in the number of DEGs, while upward lines indicate more DEGs found when the analysis focused only on the mPCs. ∗ indicates p ≤ 0.05; ∗∗ p ≤ 0.01; ∗∗∗ p ≤ 0.001; ∗∗∗∗ p ≤ 0.0001; and n.s. non-significant differences, as determined by the Wilcoxon test. (C) UMAP based on the single-cell transcriptome of a downsampled Seurat object with a color code of CytoTRACE score (left), and a superplot of the mean CytoTRACE score per sample group by diagnosis (right). Statistical testing was performed as in (B). (D) Boxplot of normalized UMIs detected in each sample, color coded by diagnosis, including myeloma-related markers, and commonly up- and down-regulated markers. (E) Heatmap of the fraction of PCs with myeloma IGH translocations detected by FISH (top), and boxplots of normalized UMIs of associated oncogene expression levels (next three rows). (F) Circos plots of three t(11;14) + myelomas evaluated by Lumpy using WGS data from germline and tumor-matched samples. (G) Heatmap of the fraction of cells with inferred large chromosomal gains (red) or losses (blue) in each PC population organized by diagnosis. Total number of PCs isolated and the fraction of mPCs in each sample are represented at the top. These plots include a dataset of pPC samples ( n = 4), and mPCs from patients with MGUS ( n = 11), SMM ( n = 22), NDMM ( n = 17), RRMM ( n = 15), and PCL ( n = 2).

Techniques Used: Biomarker Discovery, Expressing, Isolation

Figure Legend Snippet:

Techniques Used: Recombinant, Selection, Cell Isolation, Proliferation Assay, Staining, Enzyme-linked Immunosorbent Assay, Detection Assay, Reporter Assay, RNA Sequencing, Transgenic Assay, Software

Similar Products

Image Search Results

Journal: Cell Reports Medicine

Article Title: Single-cell analysis of neoplastic plasma cells identifies myeloma pathobiology mediators and potential targets

doi: 10.1016/j.xcrm.2024.101925

Figure Lengend Snippet: Inter-patient heterogeneity (A) UMAPs representing scRNA-seq data from enriched PCs from all patients with color codes representing unique samples (left), mPC and pPC populations (middle), and mPCs and pPCs by diagnosis (right). (B) Number of genes detected as dysregulated with a log2 FC of ≥ 0.5 or ≤ −0.5 when the analysis was conducted using all CD138 + PCs, or CD138 + mPCs from each sample identified by scBCR-seq, using “ FindAllMarkers ” in Seurat. Horizontal lines indicate little to no difference in the number of DEGs, while upward lines indicate more DEGs found when the analysis focused only on the mPCs. ∗ indicates p ≤ 0.05; ∗∗ p ≤ 0.01; ∗∗∗ p ≤ 0.001; ∗∗∗∗ p ≤ 0.0001; and n.s. non-significant differences, as determined by the Wilcoxon test. (C) UMAP based on the single-cell transcriptome of a downsampled Seurat object with a color code of CytoTRACE score (left), and a superplot of the mean CytoTRACE score per sample group by diagnosis (right). Statistical testing was performed as in (B). (D) Boxplot of normalized UMIs detected in each sample, color coded by diagnosis, including myeloma-related markers, and commonly up- and down-regulated markers. (E) Heatmap of the fraction of PCs with myeloma IGH translocations detected by FISH (top), and boxplots of normalized UMIs of associated oncogene expression levels (next three rows). (F) Circos plots of three t(11;14) + myelomas evaluated by Lumpy using WGS data from germline and tumor-matched samples. (G) Heatmap of the fraction of cells with inferred large chromosomal gains (red) or losses (blue) in each PC population organized by diagnosis. Total number of PCs isolated and the fraction of mPCs in each sample are represented at the top. These plots include a dataset of pPC samples ( n = 4), and mPCs from patients with MGUS ( n = 11), SMM ( n = 22), NDMM ( n = 17), RRMM ( n = 15), and PCL ( n = 2).

Article Snippet: EasySepTM Human CD138 Positive Selection Kit II , StemCell Technologies , 17877.

Techniques: Biomarker Discovery, Expressing, Isolation

Journal: Cell Reports Medicine

Article Title: Single-cell analysis of neoplastic plasma cells identifies myeloma pathobiology mediators and potential targets

doi: 10.1016/j.xcrm.2024.101925

Figure Lengend Snippet:

Article Snippet: EasySepTM Human CD138 Positive Selection Kit II , StemCell Technologies , 17877.

Techniques: Recombinant, Selection, Cell Isolation, Proliferation Assay, Staining, Enzyme-linked Immunosorbent Assay, Detection Assay, Reporter Assay, RNA Sequencing, Transgenic Assay, Software